Progress in the study of molecular markers in the prognosis assessment and recurrence patterns of glioblastoma.

IF 5.7 4区医学 Q2 ONCOLOGY

Cancer Biology & Therapy Pub Date : 2025-12-31 Epub Date: 2025-11-07 DOI:10.1080/15384047.2025.2574179

Yuqing Hu, Xiaoqin Ge, Qianyun Xie, Ruishuang Ma, Qingsong Tao

引用次数: 0

Abstract

Glioblastoma multiforme (GBM), the most invasive primary malignant tumor of the central nervous system, is characterized by an extremely poor prognosis and a high recurrence rate. Its significant molecular heterogeneity challenges precise diagnosis and treatment. Recently, with the rapid development of molecular pathology, the combination of histological and molecular typing has become the mainstream method for GBM diagnosis. Here, we review the impact of classic molecular markers on patient prognosis in GBM, as well as the different values of traditional and novel molecular markers in prognosis assessment. We initially discuss the correlation between molecular markers and recurrence, as well as the research progress of molecular markers in emerging technological fields. Moreover, we propose the challenges currently faced by molecular markers in glioblastoma and discuss future research directions in this field.

Abstract Image

查看原文本刊更多论文

分子标志物在胶质母细胞瘤预后评估及复发模式中的研究进展。

多形性胶质母细胞瘤（GBM）是侵袭性最强的中枢神经系统原发性恶性肿瘤，预后极差，复发率高。其显著的分子异质性挑战了精确的诊断和治疗。近年来，随着分子病理学的快速发展，组织分型与分子分型相结合已成为GBM诊断的主流方法。本文综述经典分子标志物对GBM患者预后的影响，以及传统分子标志物与新型分子标志物在预后评估中的不同价值。本文首先讨论了分子标记与复发的关系，以及分子标记在新兴技术领域的研究进展。此外，我们提出了胶质母细胞瘤分子标记目前面临的挑战，并讨论了该领域未来的研究方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Biology & Therapy 医学-肿瘤学

CiteScore

7.00

自引率

0.00%

发文量

审稿时长

2.3 months

期刊介绍： Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.